References
- Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
- Kuehl W, Bergsagel P L. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–187
- Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. Br J Haematol 2003; 123: 758–769
- Taube T, Beneton M NC, McCloskey E V, Rogers S, Greaves M, Kanis J A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992; 49: 192–198
- Klein B, Zhang X, Lu Z, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863–872
- Heider U, Hofbauer L C, Zavrski I, Kaiser M, Jakob C, Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005; 338: 687–693
- Giuliani N, Rizzoli V, Roodman G D. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992–3996
- Wallace S R, Oken M M, Lunetta K L, Panoskaltsis-mortari A, Masellis A M. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001; 91: 1219–1230
- Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block Runx2/Cbfa1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472–2483
- Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494
- Pittenger M F, Mackay A M, Beck S C, Jaiswal R K, Douglas R, Mosca J D, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147
- Doucet C, Ernou I, Zhang Y, Llense J R, Begot L, Holy X, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005; 205: 228–236
- Pfaffl M W, Horgan G W, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36
- Conget P A, Minguell J J. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 1999; 181: 67–73
- D'Ippolito G, Schiller P C, Ricordi C, Roos B A, Howard G A. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res 1999; 14: 1115–1122
- Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne M N, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 156–163
- Haaber J, Knudsen L M, Dahl I M, Abildgaard N, Lodahl M, Rasmussen T. Myeloma cell expression of candidate genes for osteolytic bone disease—over-expression of DKK1 correlates with clinical bone involvement. Blood 2006; 108, abstract 3406
- Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy J D, jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–2111
- Westendorf J J, Kahler R A, Schroeder T M. Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341: 19–39
- Gregory C A, Perry A S, Reyes E, Conley A, Gunn W G, Prockop D J. Dkk-1-derived synthetic peptides and lithium chloride for the control and recovery of adult stem cells from bone marrow. J Biol Chem 2005; 280: 2309–2323
- Gunn W G, Conley A, Deininger L, Olson S D, Prockop D J, Gregory C A. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and IL-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2005; 2: 986–991
- Lokhorst H M, Lamme T, de Smet M, Klein S, de Werger R A, Van Oers R, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269–2277
- Rigolin G M, Fraulini C, Ciccone M, Mauro E, Bugli A M, De Angeli C, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006; 107: 2531–2535
- Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy 2005; 7: 36–45
- Horwitz E M, Gordon P L, Koo W K, Marx J C, Neel M D, McNall R Y, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932–8937